Barif tablets are indicated for the chronic management of hyperuricemia in patients with gout
Barif tablets are indicated for the chronic management of hyperuricemia in patients with gout. Barif tablets are not recommended for the treatment of asymptomatic hyperuricemia.
Febuxostat is a non-purine, selective xanthine oxidase (XO) inhibitor. It decreases serum uric acid level by inhibiting xanthine oxidase, which is responsible for uric acid production. Xanthine oxidase breaks down hypoxanthine to xanthine and thus to uric acid. Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.
Febuxostat is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline.
The most commonly reported adverse reactions are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema. These adverse reactions were mostly mild or moderate in severity. Rare serious hypersensitivity reactions to Barif have observed.
Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Febuxostat should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Caution should be exercised when Febuxostat is administered to a nursing woman.
Gout Flare: An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including Barif. If a gout flare occurs during treatment, Barif need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti-inflammatory drug (NSAID) or colchicine upon initiation of treatment) may be beneficial for up to six months.
Cardiovascular Events: A higher rate of cardiovascular thromboembolic events was observed in patients treated with Barif than allopurinol in clinical trials. Monitor for signs and symptoms of MI and stroke.
Liver Enzyme Elevation: Transaminase elevations have been observed in Barif -treated patients. Monitor liver function tests periodically.
Febustat was studied in healthy subjects in doses up to 300 mg daily for seven days without evidence of dose-limiting toxicities.
Drugs used in Gout
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
